News

Additionally, Agenus obtained an exclusive license to a phage display library from IONTAS, and entered into an agreement for cell line development technology with Selexis. These new capabilities,

MD Anderson will leverage its expertise in developing allogeneic umbilical cord blood and peripheral blood derived NK-cell therapies and combine it with CytomX’s Probody technology to address new

Sotagliflozin (LX4211) is an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for diabetes patients.

JKB-122 is a TLR4 (Toll-like Receptor 4) antagonist on patients with AIH who are refractory to or intolerant to the existing standard of care (SOC). Duke Clinical Research

Under the PAZOFOS randomized, controlled clinical study, OxiGENE plans to enroll up to 128 patients at up to ten sites in the UK. It includes a phase 1b

The company plans to extend the existing indication for Opdivo to include the treatment of adult patients with advanced RCC after prior therapy. Validation confirms that the application

Genvoya, a combination tablet approved as a complete regimen, is designed to treat earlier untreated patients weighing about 35 kilograms. It features elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide.

Both companies have worked very closely to launch a new solution that takes advantage of the 16 years of pioneering experience Planbox has in the Innovation Management and

The program, which will be managed by Idis MA, will enable individual adolescents and children as young as 12 months old with high risk neuroblastoma to receive UNITUXIN